ASCO 2023: aanbevolen abstracten voor borstkanker van vooraanstaande oncologen wereldwijd

1 juni 2023: Bron: ASCO 2023

Aankomende week is er weer ASCO van 2 Juni - 6 Juni 2023. Vooraanstaande oncologen wereldwijd bevelen specifieke abstracten aan gerelateerd aan borstkanker.

Hier plaats ik die abstracten. Klik op de nummers van het abstract voor het abstract in te zien.

Als eerste de aanbevolen abstracten van Dr. Reshma Mahtani, Chief of Breast Medical Oncology aan het Miami Cancer Institute en een Associate Editor van het PracticeUpdate Center of Excellence for Metastatic Breast Cancer.

Daaronder aanbevolen abstracten van andere borstkankerspecialisten:

Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Breast Cancer—Local/Regional/Adjuvant

LBA500 Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial. D Slamon, D Stroyakovskiy, D Yardley, et al

Take-Home Message

Although the majority of patients with HR+/HER2− early breast cancer (EBC) do well without evidence of recurrence, there remains a need for additional well-tolerated treatments that reduce the risk of recurrence beyond hormonal therapy alone. The current approval for abemaciclib for high-risk EBC covers patients with node-positive disease. Based on the results of the NATALEE trial, there may be an opportunity to offer adjuvant CDK4/6 inhibitor therapy to patients with high-risk node-negative disease as well, expanding our use of this important class of therapy.
Depending on the magnitude of benefit and the toxicity profile, these results have the potential to be practice-changing.

503 Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. R Gray, R Bradley, J Braybrooke, et al

Sunday, June 4, 2023; 8:00 AM–11:00 AM CDT
Poster Session
Breast Cancer–Metastatic

1059 Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study. L Gerratana, Y Ren, C Reduzzi, et al

Sunday, June 4, 2023; 11:30 AM–1:00 PM CDT
Poster Discussion Session
Breast Cancer

1020 Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04. S Modi, N Niikura, T Yamashita, et al

1022 Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. R Abelman, L Spring, G Fell, et al

Sunday, June 4, 2023; 4:30 PM–6:00 PM CDT
Poster Discussion Session
Breast Cancer—Local/Regional/Adjuvant

525 Long-term oncologic outcomes after omitting axillary surgery in older women with early stage, node-negative breast cancer: A systematic review and meta-analysis. M Rana, S Lee, A Lindsay, et al

Monday, June 5, 2023; 11:30 PM–2:30 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

1001 Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. A Llombart-Cussac, C Harper-Wynne, A Perello, et al

Take-Home Message

In clinical practice, we often consider continuation of a CDK4/6 inhibitor beyond progression, especially in patients who have experienced long periods of disease control. The value of this approach has not been definitively answered, although the phase II MAINTAIN trial provided some support to it.
The PALMIRA trial evaluates whether palbociclib rechallenge combined with second–line endocrine therapy upon progression on a prior palbociclib–based therapy will improve progression–free survival over endocrine therapy alone in patients with HR+/HER2− metastatic breast cancer and will provide additional guidance regarding sequencing hormonal and targeted therapies in the metastatic setting.

1003 Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). S Tolaney, A Bardia, F Marmé, et al

Take-Home Message

The availability of antibody–drug conjugates for the treatment of HR+/HER2− metastatic breast cancer has expanded treatment options for a considerable number of patients. As the goal of therapy is palliation, it is important to understand the efficacy and safety of these new agents, which will help to optimize sequencing therapies.
An overall survival benefit was previously reported for sacituzumab govitecan as compared with treatment of physician’s choice in the TROPICS-02 trial, and the current final overall survival analysis will be important to help further characterize the efficacy benefits seen with this potent antibody–drug conjugate.

1007 Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Q Khan, C Bohnenkamp, T Monson, et al

Aanbevolen abstracten gerelateerd aan borstkanker van Professor Lillie Shockney, Associate Editor van het PracticeUpdate Center of Excellence Metastatic Breast Cancer:

Saturday, June 3, 2023; 1:15 PM–2:45 PM CDT
Clinical Science Symposium
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response

1011 RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial. H Huebner, M Rübner, A Schneeweiss, et al

Take-Home Message

The aim of this study was to understand the association between the circulating immune repertoire and treatment response using blood samples from participants in the GeparNuevo trial, which investigated the CPI durvalumab in addition to standard chemotherapy in patients with TNBC. To this end, RNA from circulating leucocytes from 117 patients was extracted and analyzed and expression of 290 immune-related genes was quantified.
The study results appear to establish an association of treatment outcomes (pCR, DDFS, iDFS, OS, and irAEs) with RNA expression levels of circulating immune cells, and the association appears to hold whether the patient is treated with CPI or with standard chemotherapy alone.

Sunday, June 4, 2023; 8:00 AM–11:00 AM CDT
Poster Session
Breast Cancer–Metastatic

1034 Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor. B Wang, S You, Y Xie, et al

1075 Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors. JF Antrás, S El Ghamrasni, J Zou, et al

Monday, June 5, 2023; 11:30 PM–2:30 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

Take-Home Message

The availability of antibody–drug conjugates for the treatment of HR+/HER2− metastatic breast cancer has expanded treatment options for a considerable number of patients. As the goal of therapy is palliation, it is important to understand the efficacy and safety of these new agents, which will help to optimize sequencing therapies.
An overall survival benefit was previously reported for sacituzumab govitecan as compared with treatment of physician’s choice in the TROPICS-02 trial, and the current final overall survival analysis will be important to help further characterize the efficacy benefits seen with this potent antibody–drug conjugate.

Monday, June 5, 2023; 1:15 PM–4:15 PM CDT
Poster Session
Symptoms and Survivorship

12049 Overall survival outcomes in older patients with metastatic breast cancer: A National Cancer Database analysis. R Patel, D Kwon, A Tiersten

Take-Home Message

The National Cancer Database was tapped to provide overall survival (OS) data of older women (≥75 years) with metastatic breast cancer to determine the influence of demographic factors and tumor characteristics.
The 5-year OS improved over time, from 13.7% in 2010 to 15.2% in 2015. The 3-year OS rates were worst for the group ≥85 years, and a greater degree of comorbidities was associated with worse outcomes. HR+/HER2− disease was associated with the best prognosis, with an OS rate of 35.1% at 3 years, compared with the poorest prognosis associated with HR−/HER2− disease with a 9.7% rate of OS.

12120 Unveiling inequities in palliative care and clinical trial participation among patients with metastatic breast cancer in the state of Florida. OT Oladeru, Y-R Hong, F Giap, JA Bradle

Publication Only
Breast Cancer—Metastatic

E13000 D-dimer as a predictive biomarker of response to chemotherapy in patients with metastatic breast cancer. L Alkhoder, S Alwassouf, M Salamoon, M Saifo

E13045 De novo metastatic Her2+ breast cancer in a diverse population of women under age 40. V Chung, MA Sheen, M Henry, et al

Take-Home Message

Results of this retrospective chart review performed on data from 746 women under the age of 40 diagnosed with breast cancer indicate that de novo metastatic disease is more likely to be HER2-postive than other subtypes in this young age group.

E13070 The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3. A Pilehvari, GG Kimmick, WYou, et al

Publication Only
Health Services Research and Quality Improvement

E18623 Real world evidence for continuing HER2-directed therapy for metastatic breast cancer. EB Jackson, N LeVasseur, L Corke, et al

Aanbevolen abstracten gerelateerd aan borstkanker van Dr. Lee Schwartzberg, hoofd medische oncologie en hematologie aan het Renown Institute for Cancer en hoogleraar klinische geneeskunde aan de Universiteit van Nevada, Reno,

Dr. Lee Schwartzberg, Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno, recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held June 2 through June 6, 2023, in Chicago.

Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Breast Cancer—Local/Regional/Adjuvant

Take-Home Message

Although the majority of patients with HR+/HER2− early breast cancer (EBC) do well without evidence of recurrence, there remains a need for additional well-tolerated treatments that reduce the risk of recurrence beyond hormonal therapy alone. The current approval for abemaciclib for high-risk EBC covers patients with node-positive disease. Based on the results of the NATALEE trial, there may be an opportunity to offer adjuvant CDK4/6 inhibitor therapy to patients with high-risk node-negative disease as well, expanding our use of this important class of therapy.
Depending on the magnitude of benefit and the toxicity profile, these results have the potential to be practice changing.

501 Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). EP Hamilton, JH Kim, N Eigeliene, et al

Take-Home Message

This is a patient-level meta-analysis of approximately 15,000 women receiving ovarian suppression conducted to better understand the impact of ovarian suppression and patient selection for it.

LBA506 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). J Cortes, JM Pérez-García, M Ruiz-Borrego, et al

Take-Home Message

PHERGain is a unique study looking at PET response–guided preoperative therapy for early-stage HER2+ breast cancer.
It provides important data looking at 3-year invasive survival outcomes with a chemotherapy-free approach with HER2 blockade compared with standard TCHP.

Saturday, June 3, 2023; 4:30 PM–5:30 PM CDT
Rapid Abstract Session
Breast Cancer

LBA1013 TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). Z Jiang, Q Ouyang, T Sun, et al

Monday, June 5, 2023; 11:30 PM–2:30 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

LBA1000 Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). GS Sonke, A van Ommen - Nijhof, N Wortelboer, et al

Take-Home Message

SONIA is a phase III study of first-line versus second-line CDK4/6 inhibition.
Is there an optimal position for CDK4/6 inhibition in the advanced disease setting?

1007 Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Q Khan, C Bohnenkamp, T Monson, et al

ASCO 2023, aanbevolen abstracten borstkanker, Dr. Reshma Mahtani, Lillie D. Shockney, Dr. Lee Schwartzberg